文献速递冠心病

心肌梗死后早期启用依折麦布联合他汀可改善心血管结局:SWEDEHEART 注册研究

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

基于 SWEDEHEART 注册的 35,826 例心肌梗死患者,比较出院后≤12 周(早期)、13 周至 16 个月(晚期)加用依折麦布或未加用的结局。中位随访 3.96 年,早期联合治疗 1 年 MACE 发生率最低(1.79/100 患者年),延迟或未加用与可避免的伤害相关。

要点

  • 心梗后早期(≤12 周)在他汀基础上加用依折麦布,MACE 风险低于延迟加用或单用他汀。
  • 延迟加用依折麦布或仅用高强度他汀单药治疗,与可避免的伤害相关。
  • 心梗护理路径应将早期他汀联合依折麦布作为标准治疗。

核心结论

  • 心梗后延迟联合降脂治疗或仅用高强度他汀单药与可避免的伤害相关,应早期启用他汀联合依折麦布。

研究设计与样本

  • 基于 SWEDEHEART 注册的回顾性队列,纳入 2015-2022 年因心梗住院且出院时处方他汀的降脂初治患者,共 35,826 例。
  • 采用 clone-censor-weight 与 Cox 比例风险模型,比较出院后≤12 周(早期,参照)、13 周至 16 个月(晚期)加用依折麦布或未加用者的结局。

主要发现

  • 中位年龄 65.1 岁,女性 26.0%;早期加用依折麦布 6,040 例(16.9%),晚期 6,495 例(18.1%),未加用 23,291 例(65.0%),各组高强度他汀使用率≥98%。
  • 中位随访 3.96 年(Q1-Q3:2.15-5.81 年),2,570 例发生 MACE,其中心血管死亡 440 例。
  • 1 年 MACE 发生率:早期 1.79、晚期 2.58、未加用 4.03(每 100 患者年)。
  • 与早期联合相比,晚期联合 1、2、3 年 MACE 加权风险差分别为 0.6%(95%CI 0.1%-1.1%,P<0.01)、1.1%(95%CI 0.3%-2.0%,P<0.01)、0.7%(95%CI -0.2% 至 1.3%,P=0.18),3 年 HR 1.14(95%CI 0.95-1.41)。
  • 未加用依折麦布者 1、2、3 年 MACE 风险差分别为 0.7%(95%CI 0.2%-1.3%)、1.6%(95%CI 0.8%-2.5%)、1.9%(95%CI 0.8%-3.1%,P 均<0.01),3 年 HR 1.29(95%CI 1.12-1.55);3 年心血管死亡 HR:晚期 1.64(95%CI 1.15-2.63),未加用 1.83(95%CI 1.35-2.69)。

临床怎么用

  • 心梗后应尽早(出院后≤12 周)在他汀基础上加用依折麦布,而非延迟升级或仅用高强度他汀单药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination lipid-lowering therapy (LLT) after myocardial infarction (MI) achieves lower low-density lipoprotein cholesterol (LDL-C) levels and better cardiovascular outcomes vs statin monotherapy. As a result, global guidelines recommend lower LDL-C but, paradoxically, advise treatment through a stepwise approach. Yet the need for combination therapy is inevitable as <20% of patients achieve goals with statins alone. Whether combining ezetimibe with a statin early vs late after MI results in better outcomes is unknown. OBJECTIVES: In this study, the authors sought to assess the impact of delayed treatment escalation on outcomes by comparing early vs late oral combination LLT (statins plus ezetimibe) in patients with MI. METHODS: LLT-naïve patients (SWEDEHEART registry) hospitalized for MI (2015-2022) and discharged on statins were included. Using clone-censor-weight and Cox proportional hazards models, we compared differences in risks of MACE (death, MI, stroke), components of MACE, and cardiovascular death between patients with ezetimibe added to statins ≤12 weeks after discharge as reference (early combination therapy), from 13 weeks to 16 months (late combination therapy), or not at all. RESULTS: Of 35,826 patients (median age 65.1 years, 26.0% women), 6,040 (16.9%) received ezetimibe early, 6,495 (18.1%) ezetimibe late, and 23,291 (65.0%) received no ezetimibe. High-intensity statin use was ≥98% in all groups. Over a median 3.96 years (Q1-Q3: 2.15-5.81 years), 2,570 patients had MACE (440 cardiovascular deaths). One-year MACE incidences were 1.79 (early), 2.58 (late), and 4.03 (none) per 100 patient-years. Compared with early combination therapy, weighted risk differences in MACE for late combination therapy at 1, 2, and 3 years were 0.6% (95% CI: 0.1%-1.1%; P < 0.01), 1.1% (95% CI: 0.3%-2.0%; P < 0.01), and 0.7% (95% CI: -0.2% to 1.3%; P = 0.18), and 3-year HR was 1.14 (95% CI: 0.95-1.41). For those receiving no ezetimibe, risk differences were 0.7% (95% CI: 0.2%-1.3%), 1.6% (95% CI: 0.8%-2.5%), and 1.9% (95% CI: 0.8%-3.1%; P for all <0.01; 3-year HR: 1.29 [95% CI: 1.12-1.55]). Similar differences in risk of cardiovascular death at 3 years were observed (HRs vs early: late: 1.64 [95% CI: 1.15-2.63]; none: 1.83 [95% CI: 1.35-2.69]). CONCLUSIONS: MI care pathways should implement early combination therapy with statins and ezetimibe as standard care, because delaying use of combination LLT or using high-intensity statin monotherapy is associated with avoidable harm.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Leosdottir, Schubert, Brandts, et al. Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry. J Am Coll Cardiol. 2025. PMID: 40240093. doi:10.1016/j.jacc.2025.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。